Infectious Diseases & Immunity, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK.
BMC Med. 2018 Feb 22;16(1):27. doi: 10.1186/s12916-017-1001-7.
Multidrug-resistant tuberculosis (MDR-TB) is a growing concern in meeting global targets for TB control. In high-income low-TB-incidence countries, a disproportionate number of MDR-TB cases occur in migrant (foreign-born) populations, with concerns about low adherence rates in these patients compared to the host non-migrant population. Tackling MDR-TB in this context may, therefore, require unique approaches. We conducted a systematic review and meta-analysis to identify and synthesise data on MDR-TB treatment adherence in migrant patients to inform evidence-based strategies to improve care pathways and health outcomes in this group.
This systematic review and meta-analysis was conducted in line with PRISMA guidelines (PROSPERO 42017070756). The databases Embase, MEDLINE, Global Health and PubMed were searched to 24 May 2017 for primary research reporting MDR-TB treatment adherence and outcomes in migrant populations, with no restrictions on dates or language. A meta-analysis was conducted using random-effects models.
From 413 papers identified in the database search, 15 studies reporting on MDR-TB treatment outcomes for 258 migrants and 174 non-migrants were included in the systematic review and meta-analysis. The estimated rate of adherence to MDR-TB treatment across migrant patients was 71% [95% confidence interval (CI) = 58-84%], with non-adherence reported among 20% (95% CI = 4-37%) of migrant patients. A key finding was that there were no differences in estimated rates of adherence [risk ratio (RR) = 1.05; 95% CI = 0.82-1.34] or non-adherence (RR = 0.97; 95% CI = 0.79-1.36) between migrants and non-migrants.
MDR-TB treatment adherence rates among migrants in high-income low-TB-incidence countries are approaching global targets for treatment success (75%), and are comparable to rates in non-migrants. The findings highlight that only just over 70% of migrant and non-migrant patients adhere to MDR-TB treatment. The results point to the importance of increasing adherence in all patient groups, including migrants, with an emphasis on tailoring care based on social risk factors for poor adherence. We believe that MDR-TB treatment targets are not ambitious enough.
耐多药结核病(MDR-TB)是实现全球结核病控制目标的一个日益严重的问题。在高收入、低结核病发病率国家,相当数量的耐多药结核病病例发生在移民(外国出生)人群中,与宿主非移民人群相比,这些患者的治疗依从性较低,令人担忧。因此,在这种情况下,解决耐多药结核病问题可能需要采取独特的方法。我们进行了系统评价和荟萃分析,以确定和综合有关移民患者耐多药结核病治疗依从性的数据,为改善该人群的护理途径和健康结果提供循证策略。
本系统评价和荟萃分析按照 PRISMA 指南(PROSPERO 42017070756)进行。对 Embase、MEDLINE、全球卫生和 PubMed 数据库进行了检索,检索日期截至 2017 年 5 月 24 日,检索内容为关于移民人群中耐多药结核病治疗依从性和结果的原始研究,不限制日期或语言。采用随机效应模型进行荟萃分析。
从数据库检索中确定了 413 篇论文,其中有 15 项研究报告了 258 名移民和 174 名非移民的耐多药结核病治疗结果,这些研究被纳入系统评价和荟萃分析。移民患者耐多药结核病治疗的估计依从率为 71%(95%可信区间[CI] 58-84%),20%(95% CI 4-37%)的移民患者报告不依从。一个关键发现是,移民与非移民之间的估计依从率(风险比[RR] 1.05;95% CI 0.82-1.34)或不依从率(RR 0.97;95% CI 0.79-1.36)无差异。
在高收入、低结核病发病率国家,移民中耐多药结核病治疗的依从率接近全球治疗成功目标(75%),且与非移民相当。研究结果表明,只有略多于 70%的移民和非移民患者坚持耐多药结核病治疗。研究结果强调,所有患者群体,包括移民,都需要提高治疗依从性,重点是根据社会风险因素调整护理,以提高治疗依从性。我们认为耐多药结核病治疗目标不够雄心勃勃。